Drug

Futuximab/Modotuximab Mixture

CI-DRUG-00000255Explore in graph →NCIt C91381 CIViC

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Phase 3	Trials	Jurisdictions	First approval	First trial
All cancers	Phase3	Phase 3	2	11	—	—	2010-03
Malignant Central Nervous System Neoplasm	Phase2	Phase 2	0	1	—	—	Feb 1, 2016
Malignant Lung Neoplasm	Phase2	Phase 2	0	1	—	—	2016-11

Computedclinicaltrialsci-drug-pipeline-v1Stage rules

Curated evidence

Clinical evidence (5)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–5 of 5 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
EGFR G465R1
Futuximab/Modotuximab Mixture

Clinical trials

Trials with this intervention (11)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–11 of 11 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05223673	Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer(COLSTAR)	terminated	Phase 3	7	Institut de Recherches Internationales ServierOTHER	6	Aug 20, 2024	clinicaltrials
NCT03549338	Sym004 Versus Futuximab or Modotuximab in Patients With mCRC

EGFR K467T1
Futuximab/Modotuximab Mixture + PanitumumabSubstitutes	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	accepted	EID1082 In this preclinical study on the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. In NIH3T3 cells expressing EGFR with a K467T mutation, Sym004 and panitumum… (full text at CIViC) PMID 26888827 · Sánchez-Martín et al., 2016 · Open in CIViC	civic

EGFR K467T1

Futuximab/Modotuximab Mixture + PanitumumabSubstitutes

Malignant Colorectal NeoplasmCURATED_BROADER

Predictive

Supports Sensitivity Response

accepted

EID1082

In this preclinical study on the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. In NIH3T3 cells expressing EGFR with a K467T mutation, Sym004 and panitumum… (full text at CIViC)

PMID 26888827 · Sánchez-Martín et al., 2016 · Open in CIViC

civic

EGFR Mutation1
Futuximab/Modotuximab Mixture	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	rejected	EID1056 In vitro analysis in colorectal cancer cell line NIH3T3 with EGFR mutations S492R, R451C, K467T, and G465R showed that antibody mixture Sym004 effectively bound to all mutants, whereas cetuximab and p… (full text at CIViC) PMID 26888827 · Sánchez-Martín et al., 2016 · Open in CIViC	civic

EGFR Mutation1

Futuximab/Modotuximab Mixture

Malignant Colorectal NeoplasmCURATED_BROADER

Predictive

Supports Sensitivity Response

rejected

EID1056

In vitro analysis in colorectal cancer cell line NIH3T3 with EGFR mutations S492R, R451C, K467T, and G465R showed that antibody mixture Sym004 effectively bound to all mutants, whereas cetuximab and p… (full text at CIViC)

PMID 26888827 · Sánchez-Martín et al., 2016 · Open in CIViC

civic

EGFR R451C1
Cetuximab + Futuximab/Modotuximab Mixture + PanitumumabSubstitutes	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Sensitivity Response	2	accepted	EID1081 In this preclinical study on the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. The R451C mutation showed moderate drug-receptor binding with sym004, cetux… (full text at CIViC) PMID 26888827 · Sánchez-Martín et al., 2016 · Open in CIViC	civic

EGFR R451C1

Cetuximab + Futuximab/Modotuximab Mixture + PanitumumabSubstitutes

Malignant Colorectal NeoplasmCURATED_BROADER

Predictive

Supports Sensitivity Response

accepted

EID1081

In this preclinical study on the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. The R451C mutation showed moderate drug-receptor binding with sym004, cetux… (full text at CIViC)

PMID 26888827 · Sánchez-Martín et al., 2016 · Open in CIViC

civic

EGFR S492R1
Futuximab/Modotuximab Mixture + PanitumumabSubstitutes	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Sensitivity Response	4	accepted	EID1079 In this preclinical study of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. The S492R mutation was sensitive to Sym004 and panitumumab treatment but resistant to cetu… (full text at CIViC) PMID 26888827 · Sánchez-Martín et al., 2016 · Open in CIViC	civic

EGFR S492R1

Futuximab/Modotuximab Mixture + PanitumumabSubstitutes

Malignant Colorectal NeoplasmCURATED_BROADER

Predictive

Supports Sensitivity Response

accepted

EID1079

In this preclinical study of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. The S492R mutation was sensitive to Sym004 and panitumumab treatment but resistant to cetu… (full text at CIViC)

PMID 26888827 · Sánchez-Martín et al., 2016 · Open in CIViC

civic